Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02097134 · ClinicalTrials.gov registry record · Phase 1
Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma
A Phase 1 study of Unilateral Retinoblastoma, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 12
- Study locations
NCT02097134 is a Phase 1 study of Unilateral Retinoblastoma that has completed, run by Children's Oncology Group. The registered enrollment target is 14 participants. The trial reports 12 study locations across 9 states.
The verdict
NCT02097134, a Phase 1 study of Unilateral Retinoblastoma, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 12
- Study locations
Study Summary
This pilot clinical trial studies whether unilateral group D retinoblastoma, or retinoblastoma affecting one eye that has spread to the inner jelly like part of the eye, can be treated with a new technique for delivering chemotherapy directly into the blood vessel that supplies the affected eye. This new technique is called intra-arterial injection. Giving melphalan via intra-arterial injection may make it less likely that children will need surgery to remove the eye and may reduce the amount of treatment side effects.
Conditions Studied
Interventions
- DRUG Melphalan
Study Locations (12)
California
- Children's Hospital Los Angeles - Los Angeles
- UCSF Medical Center-Parnassus - San Francisco
- UCSF Medical Center-Mission Bay - San Francisco
Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center - Houston
- M D Anderson Cancer Center - Houston
Connecticut
- Yale University - New Haven
Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center - Miami
Georgia
- Children's Healthcare of Atlanta - Egleston - Atlanta
Massachusetts
- Dana-Farber Cancer Institute - Boston
North Carolina
- Duke University Medical Center - Durham
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2014-10-31 |
| Est. Completion | 2023-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02097134
The ClinicalTrials.gov registry entry for NCT02097134 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unilateral Retinoblastoma appearing as the primary indexed condition, and to 1 intervention - of which Melphalan is the first listed.
NCT02097134 reports 12 study locations spanning 9 distinct geographic areas - top geographies include California, Texas, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02097134 about?
NCT02097134 is a clinical study titled "Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma". This pilot clinical trial studies whether unilateral group D retinoblastoma, or retinoblastoma affecting one eye that has spread to the inner jelly like part of the eye, can be treated with a new technique for delivering chemotherapy directly into the blood vessel that supplies the affected eye. Thi...
What is the current status of trial NCT02097134?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2014-10-31. Estimated completion is 2023-09-30.
What conditions does trial NCT02097134 study?
This clinical trial studies the following conditions: Unilateral Retinoblastoma.
What interventions are being tested in trial NCT02097134?
The interventions under investigation include: Melphalan (DRUG).
Who is sponsoring clinical trial NCT02097134?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02097134 being conducted?
This trial has 12 study locations across California, Connecticut, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unilateral Retinoblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.